The licence opens up potential international markets for its cannabis-based medicines.
() has received a Licence to Export Cannabis from Australia’s Office of Drug Control.
The export licence will allow Medlab to undertake more formal overseas trade conversations with confidence in the knowledge that the company can now supply legally overseas.
Medlab’s CEO Dr Sean Hall said: “This Licence is a welcome addition to our other approvals, allowing Medlab to research, manufacture, conduct research trials, supply within Australia, and now, pending the right partner, foreign markets.”
WATCH: Medlab's Hall: "Time to offer something new" to challenge reliance on opioids
Medlab has developed two cannabis-based medicines, NanaBis™ and NanaBidial™, which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).
NanaBis™ has a 1:1 ratio of CBD:THC and NanaBidial™ has a 18:2 ratio of CBD:THC.
Medlab also has a patented delivery platform called NanoCelle™ which delivers medicine in a tiny particle form in a spray into the mouth.
Recently Medlab received preliminary results from the University of Sydney’s Nano Institute, School of Pharmacy validating the science behind the NanoCelle™ delivery platform.
READ: Medlab Clinical Ltd advances research amid nutraceuticals revenue growth
Medlab is developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE